MSN
COVID-19: MSN Laboratories initiates phase III clinical trial of Molnupiravir for India
Kolkata: MSN Laboratories Pvt. Ltd. (MSN), the front-runner in introducing various drugs in the treatment of Covid-19 and its complications, post its launch of Posaone (Posacanazole) tab & IV in the treatment of black fungus, announced on Tuesday that MSN is initiating phase III clinical trial of Molnupiravir capsules for the treatment of Covid-19 in India.
MSN has received its clinical trial approval on 19th May 2021, from Drug Controller General of India's to perform Molnupiravir Capsules efficacy and safety study on Mild to Moderate COVID-19 patients.
MSN will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon.
The clinical trials will be performed on more than 2400 subjects suffering from mild to moderate COVID-19.
Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for COVID treatment.
MSN R&D team has developed both the API and Formulation, is expecting to launch soon after successful conclusion of clinical study followed by regulatory approval.
As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules and licensed Baridoz (Baricitinib) recently with Eli Lilly. For availability of all COVID Drugs from MSN, patients can contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com for further assistance.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
